home / stock / aclx / aclx news


ACLX News and Press, Arcellx Inc. From 04/08/22

Stock Information

Company Name: Arcellx Inc.
Stock Symbol: ACLX
Market: NASDAQ
Website: arcellx.com

Menu

ACLX ACLX Quote ACLX Short ACLX News ACLX Articles ACLX Message Board
Get ACLX Alerts

News, Short Squeeze, Breakout and More Instantly...

ACLX - Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting

Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting PR Newswire -- ACLX-002 completely regresses multiple c...

ACLX - Arcellx reports FY results

Arcellx press release (NASDAQ:ACLX): FY Cash cash and euivalents $104.6M Net loss of $65M. For further details see: Arcellx reports FY results

ACLX - Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results

Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results PR Newswire -- Completed upsized initial public offering of common stock, raising $142.3 million in gross proceeds including full exercise of underwriters' option to purch...

ACLX - Arcellx hits 52-week low, stock hovering around IPO price

Arcellx (ACLX) stock hit a 52-week low on Tuesday before modestly moving higher in late morning trading. Shares of the biotech group recently changed hands at $15.09, up 3% at approximately 11:00 a.m. ET. Arcellx shares opened at $14.52, sinking to a 52-week low of $14.18 before moving higher...

ACLX - Arcellx Announces Participation at the Barclays Global Healthcare Conference

Arcellx Announces Participation at the Barclays Global Healthcare Conference PR Newswire FOSTER CITY, Calif. , March 10, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage cell therapy biotechnology company, announced today that chairman and chie...

ACLX - Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022

Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022 PR Newswire FOSTER CITY, Calif. , ...

ACLX - Stocks To Watch: Spotlight On Ukraine, FOMC Speakers, Target, Lucid And DraftKings

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

ACLX - Catalyst watch for next week: DraftKings event, Lucid earnings and eyes on OPEC

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Previous 10 Next 10